The Large Quasar Reference Frame (LQRF) - an optical representation of the ICRS

The large number and all-sky distribution of quasars from different surveys, along with their presence in large, deep astrometric catalogs,enables the building of an optical materialization of the ICRS following its defining principles. Namely: that it is kinematically non-rotating with respect to the ensemble of distant extragalactic objects; aligned with the mean equator and dynamical equinox of J2000; and realized by a list of adopted coordinates of extragalatic sources. Starting from the updated and presumably complete LQAC list of QSOs, the initial optical positions of those quasars are found in the USNO B1.0 and GSC2.3 catalogs, and from the SDSS DR5. The initial positions are next placed onto UCAC2-based reference frames, following by an alignment with the ICRF, to which were added the most precise sources from the VLBA calibrator list and the VLA calibrator list - when reliable optical counterparts exist. Finally, the LQRF axes are inspected through spherical harmonics, contemplating to define right ascension, declination and magnitude terms. The LQRF contains J2000 referred equatorial coordinates for 100,165 quasars, well represented across the sky, from -83.5 to +88.5 degrees in declination, and with 10 arcmin being the average distance between adjacent elements. The global alignment with the ICRF is 1.5 mas, and the individual position accuracies are represented by a Poisson distribution that peaks at 139 mas in right ascension and 130 mas in declination. It is complemented by redshift and photometry information from the LQAC. The LQRF is designed to be an astrometric frame, but it is also the basis for the GAIA mission initial quasars' list, and can be used as a test bench for quasars' space distribution and luminosity function studies.Comment: 23 pages, 23 figures, 6 tables Accepted for publication by Astronomy & Astrophysics, on 25 May 200

INTEnsive care bundle with blood pressure reduction in acute cerebral hemorrhage trial (INTERACT3): study protocol for a pragmatic stepped-wedge cluster-randomized controlled trial

Background: Early intensive blood pressure (BP) lowering remains the most promising treatment for acute intracerebral hemorrhage (ICH), despite discordant results between clinical trials and potential variation in the treatment effects by approach to control BP. As the third in a series of clinical trials on this topic, the INTEnsive care bundle with blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT3) aims to determine the effectiveness of a goal-directed care bundle protocol of early physiological control (intensive BP lowering, glycemic control, and pyrexia treatment) and reversal of anticoagulation, in acute ICH. Methods: INTERACT3 is a pragmatic, international, multicenter, stepped-wedge (4 phases/3 steps), cluster-randomized controlled trial to determine the effectiveness of a multifaceted care package in adult (age ≥ 18 years) patients (target 8360) with acute ICH (< 6 h of onset) recruited from 110 hospitals (average of 19 consecutive patients per phase) in low- and middle-income countries. After a control phase, each hospital implements the intervention (intensive BP lowering, target systolic < 140 mmHg; glucose control, target 6.1–7.8 mmol/L and 7.8–10.0 mmol/L in those without and with diabetes mellitus, respectively; anti-pyrexia treatment to target body temperature ≤ 37.5 °C; and reversal of anticoagulation, target international normalized ratio < 1.5 within 1 h). Information will be obtained on demographic and baseline clinical characteristics, in-hospital management, and 7-day outcomes. Central trained blinded assessors will conduct telephone interviews to assess physical function and health-related quality of life at 6 months. The primary outcome is the modified Rankin scale (mRS) at 6 months analyzed using ordinal logistic regression. The sample size of 8360 subjects provides 90% power (α = 0.05) to detect a 5.6% absolute improvement (shift) in the primary outcome of the intervention versus control standard care, with various assumptions. Discussion: As the largest clinical trial in acute ICH, INTERACT3 is on schedule to provide an assessment of the effectiveness of a widely applicable goal-directed care bundle for a serious condition in which a clearly proven treatment has yet to be established. Trial registration: ClinicalTrials.gov NCT03209258. Registered on 1 July 2017. Chinese Trial Registry ChiCTR-IOC-17011787. Registered on 28 June 201